ArticleCureus2023
Hydralazine-Induced Vasculitis.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- Acral palpable purpura in a patient with nephritis and shortness of breath.JAAD case reports · 2026Article
- When cellulitis isn't cellulitis: A case of rapidly progressive cutaneous hemorrhagic bullae and purpura with mucosal involvement.JAAD case reports · 2026Article
- Hydralazine-induced antineutrophil cytoplasmic antibody vasculitis with significant dermatologic manifestations.JAAD case reports · 2026Article
- Hydralazine-Induced Antineutrophil Cytoplasmic Antibody Vasculitis Causing Gastroduodenal Artery Perforation.Cureus · 2026Article
- Article
- Drug-Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches-A Narrative Review.Health science reports · 2025Article
- Article
- Diffuse Alveolar Hemorrhage Linked to Hydralazine.Journal of Brown hospital medicine · 2024Article
- Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.BMC nephrology · 2023Article
- Hydralazine-Induced Vasculitis: Case Insights and Literature Review for Informed Clinical Recognition and Management.Cureus · 2023Article
- Article
- Antineutrophil cytoplasmic antibody-associated vasculitis predominantly manifesting tubulointerstitial nephritis: A case report.SAGE open medical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydralazine is a commonly prescribed medication which is used in the treatment of hypertension. While it is generally considered to be a safe and effective treatment, in rare cases it can cause a serious side effect known as hydralazine-induced vasculitis. Here we discuss this rare presentation in the form of a case report in a 67-year-old female with a past medical history of chronic obstructive pulmonary disease (COPD), congestive heart failure, hypertension, hyperlipidemia, left renal artery stenosis status post stenting who presented in the nephrology office for evaluation of recent worsening kidney function, and on further evaluation was found to have hematuria and proteinuria in the urine analysis. On further workup, she was noted to have severely elevated myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) titers with renal biopsy revealed very focal crescentic glomerulonephritis, an increased number of occlusive red blood cell cast with acute tubular necrosis. Mild interstitial fibrosis of <20% was seen and a diagnosis of drug-induced vasculitis from hydralazine was made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.